Is JAMA Cardiology a Good Journal? An Honest Assessment
is jama cardiology a good journal: JAMA Cardiology wants practice-changing clinical trials, not basic science. 14.1 IF, 8% acceptance rate. Who should subm
Associate Professor, Clinical Medicine & Public Health
Author context
Specializes in clinical and epidemiological research publishing, with direct experience preparing manuscripts for NEJM, JAMA, BMJ, and The Lancet.
Journal fit
See whether this paper looks realistic for JAMA Cardiology.
Run the Free Readiness Scan with JAMA Cardiology as your target journal and see whether this paper looks like a realistic submission.
How to read JAMA Cardiology as a target
This page should help you decide whether JAMA Cardiology belongs on the shortlist, not just whether it sounds impressive.
Question | Quick read |
|---|---|
Best for | JAMA Cardiology focuses on original clinical research that directly informs cardiovascular practice. |
Editors prioritize | Practice-changing clinical trials |
Think twice if | Submitting surrogate endpoint studies as if they're definitive |
Typical article types | Original Investigation, Research Letter, Review |
JAMA Cardiology publishes clinical research that changes cardiovascular practice, not basic science dressed up as clinical relevance. If you're asking "is JAMA Cardiology a good journal," you're probably weighing it against Circulation or European Heart Journal for a clinical trial or practice-changing study. It's a solid choice with a 14.1 impact factor and respected editorial standards, but only if your work will alter what cardiologists do Monday morning.
The journal sits in the second tier of cardiology publishing, below Circulation but above most subspecialty journals. It accepts around 8% of submissions and makes first decisions in 14-21 days, faster than many competitors. The real question isn't whether it's good (it is), but whether your study fits what JAMA Cardiology's editors actually want.
What JAMA Cardiology Actually Publishes
JAMA Cardiology focuses on original clinical research that directly informs cardiovascular practice. The editors want studies that will change treatment guidelines, alter clinical decision-making, or shift how cardiologists approach patient care.
Core content areas include:
- Randomized controlled trials comparing treatment strategies
- Large observational studies with clear practice implications
- Meta-analyses that resolve clinical controversies
- Implementation science studies showing how to apply research findings
- Health policy research affecting cardiovascular care delivery
Article types break down into Original Investigations (the majority), Research Letters (shorter studies with focused findings), Reviews (comprehensive clinical syntheses), and Viewpoints (opinion pieces on clinical controversies).
The JAMA network identity shapes editorial priorities. JAMA Cardiology inherits the parent journal's focus on clinical relevance over mechanistic novelty. Basic science studies, even excellent ones, don't fit unless they directly inform clinical practice. Translational work needs clear therapeutic implications, not just biological insights.
Geographic scope matters. JAMA Cardiology prefers studies with global relevance and diverse patient populations over single-center or regionally limited findings. The editors want research that applies across healthcare systems, not just academic medical centers or specific countries.
Disease focus areas where JAMA Cardiology publishes most frequently:
- Coronary artery disease and acute coronary syndromes
- Heart failure across the spectrum
- Cardiac arrhythmias and electrophysiology
- Structural heart disease and interventional cardiology
- Cardiovascular prevention and risk stratification
- Hypertension and cardiovascular risk factors
Notably absent: pure basic science, animal studies, and highly specialized subfield research that interests only narrow expert audiences.
JAMA Cardiology's Numbers: Impact Factor, Acceptance Rate, and What They Mean
JAMA Cardiology's 14.1 impact factor places it solidly in the second tier of cardiology journals. That's competitive but not elite. The ~8% acceptance rate reflects rigorous standards without the brutal selectivity of top-tier journals.
The 14-21 day decision timeline is genuinely fast for cardiology publishing. Most cardiovascular journals take 4-8 weeks for initial decisions. This speed reflects efficient editorial screening and a clear sense of what fits.
Context matters for these numbers:
The impact factor of 14.1 is respectable but not exceptional. It's high enough to satisfy most promotion committees and grant applications, but not so high that getting published becomes a career-defining event. For clinical cardiology work, it represents solid mainstream publication.
The 8% acceptance rate includes desk rejections, which happen frequently. Many submissions never reach peer review because they don't meet the clinical relevance threshold. The real acceptance rate for papers that clear the initial editorial screen is probably closer to 15-20%.
Decision speed varies by submission type. Original Investigations take the full 14-21 days. Research Letters often get faster decisions. Reviews and Viewpoints can take longer because they require different editorial evaluation processes.
What the numbers don't tell you: JAMA Cardiology desk-rejects aggressively. If your study uses surrogate endpoints as primary outcomes, focuses on mechanistic questions, or lacks clear practice implications, you'll get a quick rejection without peer review. The journal protects its impact factor by being selective upfront.
How JAMA Cardiology Compares to Circulation and European Heart Journal
JAMA Cardiology competes directly with Circulation (IF 38.6) and European Heart Journal (IF 35.6) but occupies a different niche in the cardiology publishing hierarchy.
Journal | Impact Factor | Focus | Geographic Scope |
|---|---|---|---|
Circulation | 38.6 | Broad cardiovascular research | Global, AHA identity |
European Heart Journal | 35.6 | Clinical cardiology emphasis | Global, ESC identity |
JAMA Cardiology | 14.1 | Practice-changing clinical research | Global, JAMA network identity |
Journal of the American College of Cardiology | 22.3 | Clinical cardiology | Global, ACC identity |
When to choose JAMA Cardiology over Circulation:
Your study is solidly clinical but not groundbreaking enough for Circulation's top tier. Circulation prioritizes large, practice-changing trials and mechanistic breakthroughs. JAMA Cardiology accepts important clinical work that doesn't meet Circulation's bar for transformative impact.
When to choose JAMA Cardiology over European Heart Journal:
You want faster decisions and don't need the European perspective. EHJ takes longer for editorial decisions and prefers studies with European investigators or patient populations. JAMA Cardiology is more geographically neutral.
When to choose JAMA Cardiology over JACC:
Your study has broad clinical implications rather than subspecialty focus. JACC publishes more specialized work through its family of journals. JAMA Cardiology prefers studies that affect general cardiology practice.
The strategic positioning is clear: JAMA Cardiology is where good clinical cardiology research goes when it's not quite good enough for Circulation or EHJ. That's not an insult. Most clinical research falls into this category, and JAMA Cardiology provides a respected home for it.
Realistic submission strategy:
If you're choosing between these journals, try Circulation or EHJ first if your study meets their criteria for transformative impact. If not, JAMA Cardiology is a strong second choice that's easier to get into and still carries significant prestige.
Don't underestimate the JAMA network effect. JAMA Cardiology papers get attention from general medicine audiences, not just cardiologists. That broader readership can increase citations and clinical impact.
The Clinical Relevance Test: What Gets Past JAMA Cardiology's Editors
JAMA Cardiology editors apply a simple test: will this study change what cardiologists do in practice? If the answer isn't clearly yes, the paper gets desk-rejected.
What "practice-changing" means concretely:
- Primary care doctors will modify their approach to cardiovascular risk assessment
- Cardiologists will prescribe different medications or use different treatment protocols
- Hospital systems will change care delivery processes based on your findings
- Professional societies will cite your work in guideline revisions
- Insurance companies will modify coverage policies based on your evidence
Basic science dressed as clinical relevance fails this test consistently. Studies showing interesting mechanisms or pathways don't qualify unless they directly inform therapeutic decisions. The editors can spot mechanistic work with forced clinical conclusions from across the room.
Examples of studies that pass the clinical relevance test:
- Randomized trials comparing two accepted treatment strategies
- Large cohort studies identifying new risk factors with actionable implications
- Implementation research showing how to apply existing evidence more effectively
- Cost-effectiveness analyses that inform resource allocation decisions
- Diagnostic studies comparing testing strategies in clinical use
Examples that fail:
- Biomarker studies that don't change clinical decision-making
- Mechanistic studies explaining how treatments work (without identifying new treatments)
- Single-center observational studies with limited generalizability
- Studies using surrogate endpoints without clear clinical validation
- Research that confirms what everyone already knows
The clinical relevance test isn't just about study design. It's about framing and implications. You need to state directly how your findings change clinical practice, not leave it for readers to infer. If you bury the clinical implications in the discussion section, you're probably not ready for JAMA Cardiology.
How to Choose the Right Journal for Your Paper (A Practical Guide) explains this decision framework in detail across specialties.
Red Flags That Lead to JAMA Cardiology Desk Rejection
Surrogate endpoints as primary outcomes. If your study measures biomarkers, imaging parameters, or laboratory values instead of clinical events, you're headed for rejection unless you can clearly link surrogates to patient outcomes.
Overstated observational findings. Claiming causation from association data or suggesting practice changes based on retrospective studies without acknowledging limitations gets you rejected fast.
Methodology buried in limitations. If your methods section looks clean but the limitations section reveals major problems with study design, data collection, or analysis, editors notice. They read limitations sections carefully.
Subspecialty focus without broad relevance. Studies that only matter to electrophysiologists, interventional cardiologists, or heart failure specialists need to demonstrate broader clinical implications or they don't fit.
Poor statistical approach to multiple comparisons, small sample sizes, or exploratory analyses presented as confirmatory. JAMA Cardiology editors know biostatistics and reject studies with fundamental analytical problems.
Submit to JAMA Cardiology If...
• Your randomized trial compares established treatment strategies with clear clinical endpoints and will influence practice guidelines
• Your large observational study identifies actionable risk factors that clinicians can use for patient management decisions
• Your meta-analysis resolves a clinical controversy by synthesizing conflicting evidence from multiple high-quality studies
• Your implementation research shows how to apply evidence more effectively in real-world clinical settings
• Your diagnostic study compares testing strategies that are actually used in clinical practice, not theoretical approaches
• Your work has global relevance with diverse patient populations and applies across different healthcare systems
• You can clearly state how your findings change clinical practice in concrete, actionable terms
Think Twice About JAMA Cardiology If...
• Your study is primarily mechanistic or basic science, even if it has potential clinical implications
• You're reporting single-center observational findings without multi-site validation or clear generalizability
• Your primary endpoints are surrogate measures like biomarkers or imaging parameters without clinical correlation
• Your work only interests subspecialty experts in narrow areas of cardiology practice
• You can't clearly explain how your findings change patient care beyond "further research is needed"
• Your study design has major limitations that you're hoping reviewers won't notice or won't care about
Desk Rejection: What It Means, Why It Happens, and What to Do Next covers what happens when these red flags lead to rejection.
Bottom Line: JAMA Cardiology's Place in Your Publishing Strategy
JAMA Cardiology is a good journal that serves an important role in cardiovascular publishing. It's not elite, but it's respected, has decent reach, and accepts work that Circulation and European Heart Journal won't take.
The journal succeeds because it knows what it is: a home for solid clinical cardiology research with clear practice implications. It doesn't try to compete on basic science or mechanistic novelty. It doesn't chase the highest impact factor by publishing only breakthrough studies. It publishes work that advances clinical practice incrementally and measurably.
Strategic positioning for your career:
Early-career researchers should view JAMA Cardiology as a realistic target for their first major clinical studies. The journal provides good visibility without the brutal competition of top-tier journals. Getting published here builds credibility for future submissions to higher-impact venues.
Mid-career researchers can use JAMA Cardiology strategically for studies that don't quite meet the bar for Circulation but deserve better than subspecialty journals. It's a solid choice for clinical work that advances the field without transforming it.
When JAMA Cardiology fits your publishing timeline:
If you need publication within 6-9 months for grant deadlines, promotion timelines, or conference presentations, JAMA Cardiology's fast editorial process is genuinely helpful. The 14-21 day initial decision means you'll know quickly whether to revise and resubmit or move to another journal.
The verdict: JAMA Cardiology is good at what it does. If your clinical cardiology research changes practice, has broad relevance, and doesn't fit at higher-tier journals, it's an excellent choice. Don't submit basic science, don't oversell observational findings, and don't expect them to publish work that only interests subspecialty experts.
10 Signs Your Paper Isn't Ready to Submit (Yet) helps you evaluate whether your manuscript meets JAMA Cardiology's standards before submission.
ManuSights provides pre-submission manuscript review to help you avoid common rejection reasons and choose the right journal for your research. We know what editors at journals like JAMA Cardiology actually want.
- Editorial decision timelines based on author surveys and journal reporting, 2024 data
- Comparative analysis of cardiovascular journal acceptance rates and editorial priorities
Jump to key sections
Sources
- 1. Journal Citation Reports 2024 - JAMA Cardiology impact factor and citation metrics
- 2. JAMA Cardiology editorial policies and submission guidelines, accessed December 2024
Final step
See whether this paper fits JAMA Cardiology.
Run the Free Readiness Scan with JAMA Cardiology as your target journal and get a manuscript-specific fit signal before you commit.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Need deeper scientific feedback? See Expert Review Options
Where to go next
Start here
Same journal, next question
Supporting reads
Conversion step
See whether this paper fits JAMA Cardiology.
Anthropic Privacy Partner. Zero-retention manuscript processing.